title: Transient allodynia pain models in mice for early assessment of analgesic activity.
abstract: OBJECTIVE
  The most common preclinical models of neuropathic pain involve surgical ligation of sensory nerves, which is especially difficult in mice. Transient models of chemically sensitized allodynia are potentially useful for rapidly characterizing the analgesic profile of compounds and conducting mechanistic studies.
  
  
  METHODS
  Increasing doses of NMDA, sulprostone (an EP1/EP3 prostaglandin receptor agonist) or phenylephrine (an alpha (1) adrenoceptor agonist) were injected intrathecally (i.t.) or i.p., and animals were subsequently assessed for allodynia. The effects of receptor antagonists and analgesic compounds on allodynia were also assessed.
  
  
  RESULTS
  A comparison of total body doses that cause allodynia following spinal or systemic administration indicated that NMDA induces allodynia in the spinal cord while sulprostone and phenylephrine act through a peripheral mechanism. Inhibition of the allodynia with receptor antagonists indicated that each agent induces allodynia by a distinct mechanism. The three models were benchmarked using compounds known to be active in neuropathic pain patients and nerve injury animal models, including gabapentin, amitriptyline and clonidine.
  
  
  CONCLUSIONS
  These transient allodynia models are a useful addition to the toolbox of preclinical pain models. They are simple, rapid and reproducible, and will be especially useful for characterizing the pain phenotype of knockout mice.
authors: Department of Biological Sciences, Allergan Inc., Irvine, CA, USA. Gil_daniel@allergan.com
authors: D W
authors: DW
authors: Gil
authors: C V
authors: CV
authors: Cheevers
authors: J E
authors: JE
authors: Donello
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000588:Amines / Q000494:pharmacology; D000639:Amitriptyline / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D003000:Clonidine / Q000494:pharmacology; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology; D015232:Dinoprostone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D000077206:Gabapentin; D006930:Hyperalgesia / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control; D007274:Injections, Intraperitoneal; D007278:Injections, Spinal; D008297:Male; D008559:Memantine / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000494:pharmacology; D016202:N-Methylaspartate / Q000008:administration & dosage*; D010146:Pain / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control; D017933:Peripheral Nervous System / Q000187:drug effects / Q000378:metabolism; D010656:Phenylephrine / Q000008:administration & dosage; D010879:Piperazines / Q000494:pharmacology; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000378:metabolism; D018078:Receptors, Prostaglandin E / Q000187:drug effects / Q000378:metabolism; D058306:Receptors, Prostaglandin E, EP1 Subtype; D015203:Reproducibility of Results; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013127:Spinal Nerves / Q000601:surgery; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D011448:Prostaglandin Antagonists; C545636:Ptger1 protein, mouse; D018340:Receptors, Adrenergic, alpha-1; D016194:Receptors, N-Methyl-D-Aspartate; D018078:Receptors, Prostaglandin E; D058306:Receptors, Prostaglandin E, EP1 Subtype; D000639:Amitriptyline; C057446:5-methylurapidil; D010656:Phenylephrine; C016767:sulprostone; D005680:gamma-Aminobutyric Acid; D016202:N-Methylaspartate; D000077206:Gabapentin; D009020:Morphine; D015232:Dinoprostone; D003000:Clonidine; D008559:Memantine
references: Neuroscience. 2001;106(1):171-82
references: 11564427
references: Anesth Analg. 2006 Jun;102(6):1768-74
references: 16717324
references: Eur J Pharmacol. 1982 Dec 17;86(1):95-8
references: 6186500
references: J Pharmacol Exp Ther. 1988 Feb;244(2):501-7
references: 3346833
references: Pain. 1988 Apr;33(1):87-107
references: 2837713
references: Science. 1991 Mar 29;251(5001):1608-10
references: 2011742
references: Pain. 1992 Sep;50(3):355-63
references: 1333581
references: Nature. 1993 Jun 10;363(6429):543-6
references: 8505981
references: Pain. 1994 May;57(2):217-23
references: 7916452
references: J Neurophysiol. 1999 Nov;82(5):2602-11
references: 10561430
references: Pain. 2000 Aug;87(2):149-58
references: 10924808
references: Brain Res. 2001 Mar 23;895(1-2):178-85
references: 11259776
references: Br J Pharmacol. 2001 Jun;133(3):438-44
references: 11375261
references: Pain. 1994 May;57(2):225-31
references: 7916453
references: Br J Pharmacol. 1994 Jul;112(3):735-40
references: 7921597
references: Br J Pharmacol. 1995 Dec;116(7):2828-37
references: 8680713
references: Brain Res. 1997 Mar 21;751(2):275-80
references: 9099815
references: Eur J Neurosci. 1999 Jun;11(6):1849-56
references: 10336652
references: Annu Rev Pharmacol Toxicol. 1980;20:441-62
references: 7387124